PAR

PARA BIO FPO [PAR]
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.2700 -1.8%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when PAR triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PAR — Free

Active Signals

Bullish Signals

  • Trading above both moving averages — the trend is your friend here
  • On a tear — up 12.5% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.54, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (1.4 quarters)
  • Pre-revenue with moderate cash ($10-30M)
  • EPS estimates revised upward (+10pts)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 51% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.38%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • RBA hiking (-3pts)

Risk Signals

  • RSI is running hot — overbought territory, so expect some pullback risk
  • Stochastic is stretched into overbought — could need a breather
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Expected next for PAR

30 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 23 Oct to 6 Nov
The last 5 moved PAR -0.6% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Melbourne Investor Lunch
NONE Appendix 4G and Corporate Governance Statement
NONE Application for quotation of securities - PAR
LOW Appendix 4E and 2026 Annual Report

Recent ASX Announcements

2026-09-02 Melbourne Investor Lunch
2026-08-28 Appendix 4G and Corporate Governance Statement
2026-08-28 Appendix 4E and 2026 Annual Report PRICE SENSITIVE
2026-08-25 Application for quotation of securities - PAR
2026-08-12 80% Safety Review Complete, September IA on Track

Key Metrics

$160.8M
Market Cap
3.4M
Avg Volume
1.3x
Vol Ratio
$0.14 — $0.47
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-457.0%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 95%
LLeader vs LaggardpassRS: 29
IInstitutional SponsorshipweakInst: 5%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:PAR vs NUZPAR vs IPDPAR vs HIQ
Share this analysis

Track PAR and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required